DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Monday. The firm issued a hold rating on the stock.

Separately, HC Wainwright reissued a buy rating and set a $10.00 target price on shares of DBV Technologies in a report on Wednesday, February 21st.

DBV Technologies Trading Down 17.8 %

DBVT stock opened at $0.57 on Monday. DBV Technologies has a 1-year low of $0.56 and a 1-year high of $2.37. The business’s 50 day simple moving average is $0.74 and its 200 day simple moving average is $0.84. The firm has a market capitalization of $110.03 million, a PE ratio of -1.46 and a beta of 0.73.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.10. The firm had revenue of $8.88 million during the quarter, compared to analysts’ expectations of $1.10 million. DBV Technologies had a negative net margin of 461.32% and a negative return on equity of 46.33%. During the same period in the previous year, the business posted ($0.23) earnings per share. As a group, sell-side analysts predict that DBV Technologies will post -0.88 EPS for the current fiscal year.

Institutional Trading of DBV Technologies

Several large investors have recently made changes to their positions in DBVT. Optiver Holding B.V. boosted its holdings in shares of DBV Technologies by 595.2% during the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock valued at $374,000 after acquiring an additional 235,337 shares in the last quarter. Landscape Capital Management L.L.C. bought a new position in DBV Technologies in the third quarter valued at about $94,000. Finally, Cowen AND Company LLC acquired a new stake in shares of DBV Technologies during the fourth quarter valued at about $49,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.